Lutetium 177‑DOTA‑TATE therapy for esthesioneuroblastoma: A case report

Sabongi,Juliano Guerra; Gonçalves,Mônica Carboni Pereira; Alves,Cira Danielle Casado; Alves,João; Scapulatempo‑Neto,Cristovam; Moriguchi,Sonia Marta

doi:10.3892/etm.2016.3732

November-2016 Volume 12 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2016 Volume 12 Issue 5

Full Size Image

Case Report

Lutetium 177‑DOTA‑TATE therapy for esthesioneuroblastoma: A case report

Authors:
- Juliano Guerra Sabongi
- Mônica Carboni Pereira Gonçalves
- Cira Danielle Casado Alves
- João Alves
- Cristovam Scapulatempo‑Neto
- Sonia Marta Moriguchi
View Affiliations / Copyright

Affiliations: Imaging Medical Center, Division of Nuclear Medicine, Medical Centre of Sorocaba, Sorocaba, SP 18031‑480, Brazil, Department of Nuclear Medicine, Barretos Cancer Hospital, Barretos, SP 14780‑000, Brazil, Department of Head and Neck Surgery, Barretos Cancer Hospital, Barretos, SP 14780‑000, Brazil, Department of Nuclear Medicine, Dr Ary Pinheiro Base Hospital, Porto Velho, RO 76804‑373, Brazil, Department of Pathological Anatomy, Barretos Cancer Hospital, Barretos, SP 18600‑000, Brazil, Department of Tropical Diseases and Diagnostic Imaging, Botucatu Medical School, São Paulo State University, Botucatu, SP 18618‑970, Brazil
Pages: 3078-3082
|
Published online on: September 20, 2016

https://doi.org/10.3892/etm.2016.3732
Expand metrics +

Abstract

Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant tumor that accounts for 3% of all tumors of the nasal cavity. The incidence of ENB is 0.4 cases per million in the general population, and the most common symptoms are nasal obstruction and epistaxis. Previous studies have indicated the presence of somatostatin receptors in this tumor type. Common treatment strategies for ENB include resection and adjuvant radiotherapy and/or chemotherapy (combined treatment); however, the rate of recurrence is high. Treatment of neuroendocrine tumors using radionuclides bound to somatostatin analogues is well established in clinical practice. However, a standard and effective therapeutic approach has not been reported for ENB. The current study described the case of a 74‑year‑old female with numerous recurrences of ENB following multiple treatments and without possibility of resection. The patient was treated with the radiolabeled‑somatostatin analogue, 177Lutetium‑DOTA‑octreotate (177Lu‑DOTA‑TATE), which successfully controlled the disease. This suggests that 177Lu‑DOTA‑TATE is a potential treatment for ENB and may represent an effective alternative and novel therapeutic strategy for this disease.

View Figures

View References

1	Berger L, Luc G and Richard D: L'esthésioneuroépithéliome olfactif. Bull Assoc Franç Étude Cancer. 13:410–421. 1924.(In French).
2	Chirico G, Pergolizzi S, Mazziotti S, Santacaterina A and Ascenti G: Primary sphenoid esthesioneuroblastoma studied with MR. Clin Imaging. 27:38–40. 2003. View Article : Google Scholar : PubMed/NCBI
3	Theilgaard SA, Buchwald C and Ingeholm P: Esthesioneuroblastoma: A Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol. 123:433–439. 2003. View Article : Google Scholar : PubMed/NCBI
4	Thompson LD: Olfactory neuroblastoma. Head Neck Pathol. 3:252–259. 2009. View Article : Google Scholar : PubMed/NCBI
5	Schiro BJ, Escott EJ, Mchugh JB and Carrau RL: Bone invasion by an esthesioneuroblastoma mimicking fibrous dysplasia. Eur J Radiol. 65:69–72. 2008.
6	Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML and Amrein PC: Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation: Results in 9 cases. Arch Otolaryngol Head Neck Surg. 123:34–40. 1997. View Article : Google Scholar : PubMed/NCBI
7	Dulguero VP, Allal AS and Calcaterra TC: Esthesioneuroblastoma: A meta-analysis and review. Lancet Oncol. 2:683–690. 2001. View Article : Google Scholar : PubMed/NCBI
8	Rinaldo R, Ferlito A, Shaha AR, Wei WI and Lund VJ: Esthesioneuroblastoma and cervical lymph node metastases: Clinical and therapeutic implications. Acta Otolaryngol. 122:215–221. 2002. View Article : Google Scholar : PubMed/NCBI
9	Pickuth D, Heywang-Köbrunner SH and Speilman RP: Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: An analysis of 22 cases. Clin Otolaryngol Allied Sci. 24:457–461. 1999. View Article : Google Scholar : PubMed/NCBI
10	Zollinger LV, Wiggins RH, Cornelius RS and Phillips CD: Retropharyngeal lymph node metastasis from esthesioneuroblastoma: A review of the therapeutic and prognostic implications. AJNR Am J Neuroradiol. 29:1561–1563. 2008. View Article : Google Scholar : PubMed/NCBI
11	de Vos FY, Willemse PH and de Vries EG: Successful treatment of metastatic esthesioneuroblastoma. Neth J Med. 61:414–416. 2003.PubMed/NCBI
12	Kadish S, Goodman M and Wang CC: Olfatory neuroblastoma. A clinical analysis of 17 cases. Cancer. 37:1571–1576. 1976. View Article : Google Scholar : PubMed/NCBI
13	Chamberlain MC: Treatment of intracranial metastatic esthesioneuroblastoma. Cancer. 95:243–248. 2002. View Article : Google Scholar : PubMed/NCBI
14	Lund VJ, Howard D, Wei W and Spittle M: Olfactory neuroblastoma: Past, present, and future? Laryngoscope. 113:502–507. 2003. View Article : Google Scholar : PubMed/NCBI
15	Eich HT, Hero B, Staar S, Micke O, Seegenschmiedt H, Mattke A, Berthold F and Müller RP: Multimodality therapy including radiotherapy and chemotherapy improves event free survival in stage C esthesioneuroblastoma. Strahlenther Onkol. 179:233–240. 2003. View Article : Google Scholar : PubMed/NCBI
16	Diaz EM Jr, Johnigan RH, Pero C, El-Naggar AK, Roberts DB, Barker JL and DeMonte F: Olfactory neuroblastoma: The 22-year experience at one comprehensive cancer center. 27. 138–49. 2005.
17	Uslu GH, Canyilmaz E, Zengin AY, Mungan S, Yoney A, Bahadir O and Gocmez H: Olfactory neuroblastoma: A case report. Oncol Letters. 10:3651–3654. 2015.
18	Bodei L, Brand J Mueller, Baum RP, Pavel ME, Hörsh D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ and Zaknun JJ: The JOINT IAEA, EANM and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 40:800–816. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO and Krenning EP: Treatment with the radiolabeled somato- statin analog [177Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 26:2124–2130. 2008. View Article : Google Scholar : PubMed/NCBI
20	De Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A and Krenning EP: ¹⁷⁷Lu-DOTA (0), Tyr3 octreotate for somatostatin receptor targeted radionuclide therapy. Int J Cancer. 92:628–633. 2001. View Article : Google Scholar : PubMed/NCBI
21	Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE and Quast LM: Esthesioneuroblastoma: Prognosis and management. Neurosurgery. 32:706–714. 1993. View Article : Google Scholar : PubMed/NCBI
22	Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D, Silbergeld DL, Futran N, Weymuller EA, Mankoff DA and Eary J: Clinical utility of somatostatin receptor scintigraphic imaging (Octreoscan) in esthesioneuroblastoma: A case study and survey of somatostatin receptor subtype expression. Head Neck. 28:305–312. 2006. View Article : Google Scholar : PubMed/NCBI
23	Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G and Riva P: In- and Y-DOTA-lanreotide: Results and implication of the MAURITIUS trial. Semin Nucl Med. 32:148–155. 2002. View Article : Google Scholar : PubMed/NCBI
24	Fitzek MM, Thornton AF and Varvares M: Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 94:2623–2634. 2002. View Article : Google Scholar : PubMed/NCBI
25	Howell MC, Branstetter BF and Snyderman CH: Patterns of Regional Spread for Esthesioneuroblastoma. AJNR AM J Neuroradiol. 32:929–933. 2011. View Article : Google Scholar : PubMed/NCBI
26	Rajesh, Shekhar S and Madhavan S: Esthesioneuroblastoma with hepatic and splenic metastasis. Indian J Radiol Imag. 13:219–222. 2003.
27	Makis W, McCann K and McEwan A: Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT. Clin Nucl Med. 4:317–321. 2015. View Article : Google Scholar